Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Average (2016 - 2026)

Intellia Therapeutics has reported Equity Average over the past 11 years, most recently at $646.2 million for Q1 2026.

  • Quarterly Equity Average fell 21.77% to $646.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $646.2 million through Mar 2026, down 21.77% year-over-year, with the annual reading at $771.7 million for FY2025, 19.71% down from the prior year.
  • Equity Average was $646.2 million for Q1 2026 at Intellia Therapeutics, down from $709.9 million in the prior quarter.
  • Over five years, Equity Average peaked at $1.2 billion in Q1 2023 and troughed at $646.2 million in Q1 2026.
  • The 5-year median for Equity Average is $966.8 million (2024), against an average of $933.3 million.
  • Year-over-year, Equity Average skyrocketed 85.84% in 2022 and then dropped 25.51% in 2025.
  • A 5-year view of Equity Average shows it stood at $1.0 billion in 2022, then increased by 1.31% to $1.0 billion in 2023, then decreased by 12.12% to $917.3 million in 2024, then dropped by 22.61% to $709.9 million in 2025, then decreased by 8.98% to $646.2 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Equity Average are $646.2 million (Q1 2026), $709.9 million (Q4 2025), and $731.8 million (Q3 2025).